Table of Contents Author Guidelines Submit a Manuscript
Bone Marrow Research
Volume 2012 (2012), Article ID 787414, 8 pages
Research Article

Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A Comparative Analysis

1Division of Translational Medicine, Nichi-In Centre for Regenerative Medicine (NCRM), C 16 & 17, Vijaya Health Centre Premises, 175 NSK Salai, Vadapalani, Chennai-600026, Tamil Nadu, India
2Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522 510, India
3Department of Medicine, KG Hospital, Arts College Road, Coimbatore 641018, India
4Department of Cardiothoracic Surgery, Omega Hospital, Mangalore, Mahaveera Circle, Kankanady, Mangalore 575002, India
5Department of Surgery, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Yamanashi, Chuo 409-3898, Japan

Received 15 February 2012; Revised 25 April 2012; Accepted 3 May 2012

Academic Editor: Mark R. Litzow

Copyright © 2012 Vidyasagar Devaprasad Dedeepiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. Recent evidence of safety and efficacy of Bone Marrow Mononuclear Cells (BMMNC) in spinal cord injury makes the Bone Marrow (BM) CD34+ percentage and the BMMNC count gain significance. The indices of BM that change with body mass index and aging in general population have been reported but seldom in Spinal Cord Injury (SCI) victims, whose parameters of relevance differ from general population. Herein, we report the indices of BMMNC in SCI victims. Materials and Methods. BMMNCs of 332 SCI patients were isolated under GMP protocols. Cell count by Trypan blue method and CD34+ cells by flow cytometry were documented and analysed across ages and gender. Results. The average BMMNC per ml in the age groups 0–20, 21–40, 41–60, and 61–80 years were 4.71, 4.03, 3.67, and 3.02 million and the CD34+ were 1.05%, 1.04%, 0.94%, and 0.93% respectively. The decline in CD34+ was sharp between 20–40 and 40–60 age groups. Females of reproductive age group had lesser CD34+. Conclusion. The BMMNC and CD34+ percentages decline with aging in SCI victims. Their lower values in females during reproductive age should be analysed for relevance to hormonal influence. This study offers reference values of BMMNC and CD34+ of SCI victims for successful clinical application.